Several recent studies have confirmed a causal relationship between gut microbiota and Alzheimer's disease (AD), but the potential mediators remain unclear.
Objective
This study aimed first to investigate the causal relationship between gut microbiota and AD, and second to explore potential mediators involved in this relationship.
Methods
We used a two-step Mendelian randomization study. Firstly, we mainly used inverse-variance weighted (IVW), weighted median, weighted mode, MR-Egger, and simple mode methods to assess the causal relationship between gut microbiota and AD. Secondly, we conducted mediation analysis to evaluate the roles of inflammatory factors, immune cells, and metabolites in this causal pathway. In addition, we performed sensitivity analysis, Steiger test, and linkage disequilibrium score regression (LDSC).
Results
Our results showed that ten types of gut microbiota were causally associated with AD, of which seven were associated with an increased risk of AD and three with a reduced risk. In addition, the mediation analysis showed that CD45 on Mo MDSC mediated 21.89% of the effect of class Actinobacteria on AD, while the cortisol to taurocholate ratio mediated 18.35% of the effect of genus Lactococcus on AD. Beta-hydroxyisovalerate and glycodeoxycholate levels respectively mediated 10.56% and 16.22% of the effects of class Betaproteobacteria on AD.
Conclusions
Our research not only supports modulating gut microbiota as a preventive measure for AD but also emphasizes the mediating roles of inflammatory factors, immune cells, and metabolites. These findings enhance our understanding of the gut-brain axis, providing new perspectives and potential targets for AD prevention.
NicholsESteinmetzJDVollsetSE, et al.Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the global burden of disease study 2019. Lancet Public Health2022; 7: e105–e125.
3.
ZhengQWangX. Alzheimer’s disease: insights into pathology, molecular mechanisms, and therapy. Protein Cell2025; 16: 83–120.
4.
Thu Thuy NguyenVEndresK. Targeting gut microbiota to alleviate neuroinflammation in Alzheimer’s disease. Adv Drug Deliv Rev2022; 188: 114418.
5.
BonfiliLCecariniVGogoiO, et al.Microbiota modulation as preventative and therapeutic approach in Alzheimer’s disease. FEBS J2021; 288: 2836–2855.
6.
VaresiAPierellaERomeoM, et al.The potential role of gut microbiota in Alzheimer’s disease: from diagnosis to treatment. Nutrients2022; 14: 668.
7.
ZhangYGengRTuQ. Gut microbial involvement in Alzheimer’s disease pathogenesis. Aging2021; 13: 13359–13371.
8.
ZhengYZhangXZhangR, et al.Inflammatory signaling pathways in the treatment of Alzheimer’s disease with inhibitors, natural products and metabolites (review). Int J Mol Med2023; 52: 111.
9.
FuXCaiHQuanS, et al.Immune cells in Alzheimer’s disease: insights into pathogenesis and potential therapeutic targets. Med Rev (2021)2025; 5: 179–202.
10.
ZhaoQBaranovaACaoH, et al.Evaluating causal effects of gut microbiome on Alzheimer’s disease. J Prev Alzheimers Dis2024; 11: 1843–1848.
11.
ZhuangZYangRWangW, et al.Associations between gut microbiota and Alzheimer’s disease, major depressive disorder, and schizophrenia. J Neuroinflammation2020; 17: 288.
12.
KurilshikovAMedina-GomezCBacigalupeR, et al.Large-scale association analyses identify host factors influencing human gut microbiome composition. Nat Genet2021; 53: 156–165.
13.
Alzheimer Disease Genetics Consortium (ADGC), The European Alzheimer’s Disease Initiative (EADI), Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium (CHARGE), et al.Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nat Genet2019; 51: 414–430.
14.
OrrùVSteriMSidoreC, et al.Complex genetic signatures in immune cells underlie autoimmunity and inform therapy. Nat Genet2020; 52: 1036–1045.
15.
ChenYLuTPettersson-KymmerU, et al.Genomic atlas of the plasma metabolome prioritizes metabolites implicated in human diseases. Nat Genet2023; 55: 44–53.
16.
ZhaoJHStaceyDErikssonN, et al.Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets. Nat Immunol2023; 24: 1540–1551.
17.
JiDChenW-ZZhangL, et al.Gut microbiota, circulating cytokines and dementia: a Mendelian randomization study. J Neuroinflammation2024; 21: 2.
18.
LvHWangZHuangC, et al.Causal links between gut microbiota, blood metabolites, immune cells, inflammatory proteins, and myopia: a Mendelian randomization study. Ophthalmol Sci2025; 5: 100684.
19.
ChenYChenC. Gut microbiota, inflammatory proteins and COVID-19: a Mendelian randomisation study. Front Immunol2024; 15: 1406291.
20.
PierceBLBurgessS. Efficient design for Mendelian randomization studies: subsample and 2-sample instrumental variable estimators. Am J Epidemiol2013; 178: 1177–1184.
21.
BowdenJDavey SmithGHaycockPC, et al.Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol2016; 40: 304–314.
22.
BowdenJDel GrecoMFMinelliC, et al.A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization. Stat Med2017; 36: 1783–1802.
23.
GrecoMFDMinelliCSheehanNA, et al.Detecting pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome. Stat Med2015; 34: 2926–2940.
24.
HemaniGTillingKDavey SmithG. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. PLoS Genet2017; 13: e1007081.
25.
Schizophrenia Working Group of the Psychiatric Genomics Consortium, Bulik-SullivanBKLohP-R, et al.LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat Genet2015; 47: 291–295.
26.
YuanMWangYHuangZ, et al.Impaired autophagy in amyloid-beta pathology: a traditional review of recent Alzheimer’s research. J Biomed Res2023; 37: 30.
27.
Abdel-HaqRSchlachetzkiJCMGlassCK, et al.Microbiome–microglia connections via the gut–brain axis. J Exp Med2019; 216: 41–59.
28.
LingZZhuMYanX, et al.Structural and functional dysbiosis of fecal microbiota in Chinese patients with Alzheimer’s disease. Front Cell Dev Biol2021; 8: 634069.
29.
JemimahSChabibCMMHadjileontiadisL, et al.Gut microbiome dysbiosis in Alzheimer’s disease and mild cognitive impairment: a systematic review and meta-analysis. PLoS One2023; 18: e0285346.
30.
ZengHZhouKZhuangY, et al.Unraveling the connection between gut microbiota and Alzheimer’s disease: a two-sample Mendelian randomization analysis. Front Aging Neurosci2023; 15: 1273104.
31.
ZhaoYJaberVRPogueAI, et al.Lipopolysaccharides (LPSs) as potent neurotoxic glycolipids in Alzheimer’s disease (AD). Int J Mol Sci2022; 23: 12671.
32.
HouMXuGRanM, et al.APOE-ε4 carrier status and gut microbiota dysbiosis in patients with Alzheimer disease. Front Neurosci2021; 15: 619051.
33.
HungC-CChangC-CHuangC-W, et al.Gut microbiota in patients with Alzheimer’s disease spectrum: a systematic review and meta-analysis. Aging2022; 14: 477–496.
34.
HeraviFSNaseriKHuH. Gut microbiota composition in patients with neurodegenerative disorders (Parkinson’s and Alzheimer’s) and healthy controls: a systematic review. Nutrients2023; 15: 4365.
35.
DisbrowEStokesKYLedbetterC, et al.Plasma hydrogen sulfide: a biomarker of Alzheimer’s disease and related dementias. Alzheimers Dement2021; 17: 1391–1402.
36.
HeXYanNZhangH, et al.Hydrogen sulfide improves spatial memory impairment and decreases production of aβ in APP/PS1 transgenic mice. Neurochem Int2014; 67: 1–8.
37.
GuoXZhangXTangP, et al.Integration of genome-wide association studies (GWAS) and microbiome data highlights the impact of sulfate-reducing bacteria on Alzheimer’s disease. Age Ageing2023; 52: afad112.
38.
CoradduzzaDSeddaSCrucianiS, et al.Age-related cognitive decline, focus on microbiome: a systematic review and meta-analysis. Int J Mol Sci2023; 24: 13680.
39.
SilvaYPBernardiAFrozzaRL. The role of short-chain fatty acids from gut microbiota in gut-brain communication. Front Endocrinol2020; 11: 25.
40.
LiuPWuLPengG, et al.Altered microbiomes distinguish Alzheimer’s disease from amnestic mild cognitive impairment and health in a Chinese cohort. Brain Behav Immun2019; 80: 633–643.
41.
ZhangLWangYXiayuX, et al.Altered gut microbiota in a mouse model of Alzheimer’s disease. J Alzheimers Dis2017; 60: 1241–1257.
42.
DuYLiXAnY, et al.Association of gut microbiota with sort-chain fatty acids and inflammatory cytokines in diabetic patients with cognitive impairment: a cross-sectional, non-controlled study. Front Nutr2022; 9: 930626.
43.
WanapaisanPChuansangeamMNopnipaS, et al.Association between gut microbiota with mild cognitive impairment and Alzheimer’s disease in a Thai population. Neurodegener Dis2022; 22: 43–54.
44.
NingMAnLDongL, et al.Causal associations between gut microbiota, gut microbiota-derived metabolites, and Alzheimer’s disease: a multivariable Mendelian randomization study. J Alzheimers Dis2024; 100: 229–237.
45.
Abg Abd WahabDYGauCHZakariaR, et al.Review on cross talk between neurotransmitters and neuroinflammation in striatum and cerebellum in the mediation of motor behaviour. Biomed Res Int2019; 2019: 1767203.
46.
SunB-LLiW-WWangJ, et al.Gut microbiota alteration and its time course in a tauopathy mouse model. J Alzheimers Dis2019; 70: 399–412.
47.
ChengXChiLLinT, et al.Exogenous monocyte myeloid-derived suppressor cells ameliorate immune imbalance, neuroinflammation and cognitive impairment in 5xFAD mice infected with Porphyromonas gingivalis. J Neuroinflammation2023; 20: 55.
48.
SalminenAKaarnirantaKKauppinenA. The potential importance of myeloid-derived suppressor cells (MDSCs) in the pathogenesis of Alzheimer’s disease. Cell Mol Life Sci2018; 75: 3099–3120.
49.
ChakrabartyPLiACeballos-DiazC, et al.IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior. Neuron2015; 85: 519–533.
50.
LesnéSDocagneFGabrielC, et al.Transforming growth factor-β1 potentiates amyloid-β generation in astrocytes and in transgenic mice. J Biol Chem2003; 278: 18408–18418.
51.
PaidiRKRahaSRoyA, et al.Muscle-building supplement β-hydroxy β-methylbutyrate binds to PPARα to improve hippocampal functions in mice. Cell Rep2023; 42: 112717.
52.
SaltoRVílchezJDGirónMD, et al.β-Hydroxy-β-Methylbutyrate (HMB) promotes neurite outgrowth in Neuro2a cells. PLoS One2015; 10: e0135614.
53.
KijpaisalratanaNPhuahC-LAmentZ, et al.White matter hyperintensity severity modifies gut metabolite association with cognitive outcomes. J Prev Alzheimers Dis2025; 12: 100086.
54.
MahmoudianDehkordiSArnoldMNhoK, et al.Altered bile acid profile associates with cognitive impairment in Alzheimer’s disease—an emerging role for gut microbiome. Alzheimers Dement2019; 15: 76–92.
55.
XingCZhangXWangD, et al.Neuroprotective effects of mesenchymal stromal cells in mouse models of Alzheimer’s disease: the mediating role of gut microbes and their metabolites via the microbiome-gut-brain axis. Brain Behav Immun2024; 122: 510–526.
56.
HuangC-WLuiC-CChangW-N, et al.Elevated basal cortisol level predicts lower hippocampal volume and cognitive decline in Alzheimer’s disease. J Clin Neurosci2009; 16: 1283–1286.
57.
TatomirAMicuCCriviiC. The impact of stress and glucocorticoids on memory. Clujul Med2014; 87: 3–6.
58.
GreenKNBillingsLMRoozendaalB, et al.Glucocorticoids increase amyloid-β and tau pathology in a mouse model of Alzheimer’s disease. J Neurosci2006; 26: 9047–9056.
59.
OuanesSPoppJ. High cortisol and the risk of dementia and Alzheimer’s disease: a review of the literature. Front Aging Neurosci2019; 11: 43.
60.
CaoDZhangYZhangS, et al.Risk of Alzheimer’s disease and genetically predicted levels of 1400 plasma metabolites: a Mendelian randomization study. Sci Rep2024; 14: 26078.
61.
ZhangAPanCWuM, et al.Causal association between plasma metabolites and neurodegenerative diseases. Prog Neuropsychopharmacol Biol Psychiatry2024; 134: 111067.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
